Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial
Download the PDF here.
This post appeared first on investingnews.com

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial
Download the PDF here.
John Rubino, who writes a newsletter on Substack, shares his ...
As the end of 2025 nears, investors may want to ...
Peter Grandich of Peter Grandich & Co. shares his key ...
Our website uses cookies to improve your experience. Learn more about: cookie policy